Cost-effectiveness of eszopiclone for the treatment of chronic insomnia.

Eszopiclone (Lunesta) is the first hypnotic to receive US FDA approval for the long-term treatment of chronic insomnia. This novel nonbenzodiazepine hypnotic provides another option for patients with sleep disorders by inducing rapid-sleep onset and sleep maintenance. The drug is effective and well tolerated in adult patients with insomnia.

Eszopiclone.

Purpose: The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, dosing, and administration of eszopiclone are discussed.

Summary: The pharmacology of eszopiclone is not well understood. Eszopiclone is the S-isomer of racemic zopiclone.

Nateglinide.

The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, interactions, and dosage of nateglinide are reviewed. Nateglinide is an oral hypoglycemic agent approved for use alone or in combination with metformin as an adjunct to diet and exercise for the treatment of type 2 diabetes mellitus. Nateglinide, an amino acid derivative of D-phenylalanine, stimulates the secretion of insulin by binding to the ATP potassium channels in pancreatic beta cells.